Article Information
History
- July 6, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chijioke Bennett1,†,
- E Joy Rivers2,
- Wayne Woo3,
- Mark Bloch4,
- King Cheung5,
- Paul Griffin6,
- Rahul Mohan7,
- Sachin Deshmukh8,
- Mark Arya9,
- Oscar Cumming10,
- A. Munro Neville11,
- Toni McCallum Pardey12,
- Joyce S Plested13,
- Shane Cloney-Clark14,
- Mingzhu Zhu15,
- Raj Kalkeri16,
- Nita Patel17,
- Agi Buchanan18,
- Alex Marcheschi19,‡,
- Jennifer Swan20,
- Gale Smith21,
- Iksung Cho22,
- Gregory M. Glenn23,
- Robert Walker24 and
- Raburn M. Mallory25 the Novavax Inc. 2019nCoV-311 Study Group
- 1Novavax, Inc., Gaithersburg, MD, 20878, USA;
- 2Novavax, Inc., Gaithersburg, MD 20878, USA;
- 3Novavax, Inc., Gaithersburg, MD 20878, USA;
- 4Holdsworth House Medical Practice, Sydney, AU and Kirby Institute, University of New South Wales, Sydney, AU;
- 5Emeritus Research, Camberwell, AU;
- 6Mater Misericordiae Ltd and University of Queensland, South Brisbane, AU;
- 7Paratus Clinical Research Western Sydney, Blacktown, AU;
- 8Griffith University, Southport, AU;
- 9Australian Clinical Research Network (ACRN), Anzac Parade Maroubra, AU;
- 10Novatrials, Newcastle, AU;
- 11AusTrials, Brisbane, AU;
- 12Novatrials, Newcastle, AU;
- 13Novavax, Inc., Gaithersburg, MD 20878, USA;
- 14Novavax, Inc., Gaithersburg, MD 20878, USA;
- 15Novavax, Inc., Gaithersburg, MD 20878, USA;
- 16Novavax, Inc., Gaithersburg, MD 20878, USA;
- 17Novavax, Inc., Gaithersburg, MD 20878, USA;
- 18Novavax, Inc., Gaithersburg, MD 20878, USA;
- 19Novavax, Inc., Gaithersburg, MD 20878, USA;
- 20Novavax, Inc., Gaithersburg, MD 20878, USA;
- 21Novavax, Inc., Gaithersburg, MD 20878, USA;
- 22Novavax, Inc., Gaithersburg, MD 20878, USA;
- 23Novavax, Inc., Gaithersburg, MD 20878, USA;
- 24Novavax, Inc., Gaithersburg, MD 20878, USA;
- 25Novavax, Inc., Gaithersburg, MD 20878, USA;